Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease

Current Hypertension Reports

Volumn 14, Issue 2, 2012, Pages 152-159

  Tanner, Rikki M ^a   Brown, Todd M ^b   Muntner, Paul ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Albuminuria; Blood pressure; Chronic kidney disease; Diabetes; End stage renal disease; Epidemiology; HDL cholesterol; Incidence; Interventions; Mechanisms; Metabolic syndrome; Obesity; Triglycerides

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; TRIACYLGLYCEROL;

ALBUMINURIA; ARTICLE; CHOLESTEROL INTAKE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FAT INTAKE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PROTEINURIA; RISK ASSESSMENT; WEIGHT REDUCTION;

ALBUMINURIA; BLOOD PRESSURE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK ASSESSMENT; UNITED STATES; WEIGHT LOSS;

EID: 84861092508     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0254-y     Document Type: Article

References (69)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303(3):235-41.
2. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-7.
3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
4. Scholze J, Alegria E, Ferri C, et al.: Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health 2010, 10:529.
5. Wild SH, Byrne CD: The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In The Metabolic Syndrome. Edited by Byrne, CD and Wild, SH. Chichester, UK: John Wiley & Sons, Ltd.; 2006:1-41.
6. Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens. 1997;15 (4):451-6. (Pubitemid 27187148)
7. Brancati FL, Whelton PK, Randall BL, et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 1997;278(23):2069-74. (Pubitemid 28016228)
8. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58(1):293-301. (Pubitemid 30429874)
9. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA. 1999;282(16):1530-8. (Pubitemid 29504046)
10. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523-9. (Pubitemid 29504045)
11. Visscher TL, Seidell JC. The public health impact of obesity. Ann Rev Public Health. 2001;22:355-75. (Pubitemid 32452512)
12. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723-7.
13. Gu D, Reynolds K, Wu X, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005;365 (9468):1398-405. (Pubitemid 40523734)
14. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. (Pubitemid 19004941)
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-53. (Pubitemid 28319935)
16. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. (Pubitemid 41532612)
17. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-62. (Pubitemid 41338752)
18. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676-81. (Pubitemid 39441469)
19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287 (3):356-9. (Pubitemid 34251969)
20. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27 (10):2444-9. (Pubitemid 39281399)
21. Liu Y, Tong G, Tong W, et al.: Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects? BMC Public Health 2011;11:35.
22. Gallagher D, Visser M, Sepulveda D, et al. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996;143(3):228-39. (Pubitemid 26032628)
23. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291 (7):844-50. (Pubitemid 38543772)
24. Munkhaugen J, Lydersen S, Wideroe TE, et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis. 2009;54(4):638-46.
25. Muntner P, Winston J, Uribarri J, et al. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med. 2008;121(4):341-8. (Pubitemid 351444785)
26. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416-21. (Pubitemid 38406982)
27. Noori N, Hosseinpanah F, Nasiri AA, et al. Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr. 2009;19(3):228-37.
28. de Boer IH, Sibley SD, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007;18(1):235-43. (Pubitemid 46053436)
29. Thomas G, Sehgal AR, Kashyap SR, et al.: Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011, 6(10):2364-2373.
30. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21-8. (Pubitemid 46780716)
31. Reynolds K, Gu D, Muntner P, et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol. 2007;18(6):1928-35. (Pubitemid 46870330)
32. Perry Jr. HM, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25(4 Pt 1):587-94.
33. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17(5):1453-9. (Pubitemid 43673427)
34. Kramer H, Shoham D, McClure LA, et al.: Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2011;58(2):177-185.
35. Teta D. Weight loss in obese patients with chronic kidney disease: who and how? J Ren Care. 2010;36 Suppl 1:163-71.
36. Kramer H, Tuttle KR, Leehey D, et al. Obesity management in adults with CKD. Am J Kidney Dis. 2009;53(1):151-65.
37. Eckel RH. Clinical practice. Nonsurgical management of obesity in adults. N Engl J Med. 2008;358(18):1941-50.
38. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115 (12):956-61.
39. Navaneethan SD, Yehnert H, Moustarah F, et al.: Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4(10):1565-1574.
40. Agrawal V, Krause KR, Chengelis DL, et al. Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis. 2009;5 (1):20-6.
41. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441-51.
42. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277(16):1293-8. (Pubitemid 27194353)
43. Vupputuri S, Batuman V, Muntner P, et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension. 2003;42(6):1144-9. (Pubitemid 37549069)
44. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118(8):577-81. (Pubitemid 23102690)
45. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulindependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271 (4):275-9. (Pubitemid 24030753)
46. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329 (20):1456-62. (Pubitemid 23335891)
47. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939-45. (Pubitemid 26114159)
48. Ruggenenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol. 1998;9(11):2096-101. (Pubitemid 28482158)
49. Guasch A, Parham M, Zayas CF, et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. J Am Soc Nephrol. 1997;8 (5):793-8. (Pubitemid 27493593)
50. Levin A, Hemmelgarn B, Culleton B, et al. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179 (11):1154-62.
51. USRDS: USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States Bethesda, MD: National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2010.
52. Salpeter SR, Greyber E, Pasternak GA, et al.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, (4):CD002967.
53. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. (Pubitemid 351831357)
54. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908-19. (Pubitemid 27252762)
55. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140 (3):167-74.
56. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336 (7645):645-51. (Pubitemid 351481234)
57. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59 (1):260-9. (Pubitemid 32055234)
58. NKF: KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Available at http://www.kidney.org/professionals/kdoqi/ guidelines-lipids/iii.htm#guide4. Accessed October 2011.
59. Lea J, Cheek D, Thornley-Brown D, et al. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008;51(5):732-40. (Pubitemid 351626250)
60. Sarafidis PA, Lasaridis AN. Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome? J Cardiometab Syndr. 2008;3(3):183-7.
61. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26(3):232-44. (Pubitemid 44114394)
62. Chung S, Park CW. Role of peroxisome proliferator-activated receptor alpha in diabetic nephropathy. Diabetes Metab J. 2011;35(4):327-36.
63. Tesauro M, Canale MP, Rodia G, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract. 2011;2011:653182.
64. Kasiske BL, O'Donnell MP, Garvis WJ, et al. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res. 1988;62(2):367-74. (Pubitemid 18041958)
65. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91(3A):7A-11.
66. Lucove J, Vupputuri S, Heiss G, et al. Metabolic syndrome and the development of CKD in American Indians: The Strong Heart Study. Am J Kidney Dis. 2008;51:21-8. (Pubitemid 350296515)
67. Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937-43. (Pubitemid 350120971)
68. Watanabe H, Obata H, Watanabe T, et al. Metabolic syndrome and risk of development of chronic kidney disease: The Niigata Preventive Medicine Study. Diabetes Metab Res Rev. 2010;26:26-32.
69. Bonnet F, Marre M, Halimi JM, et al. Waist circumference and the metabolic syndrome predict the development of elevated albuminuria in non-diabetic subjects: The DESIR Study. J Hypertens. 2006;24:1157-63. (Pubitemid 43772324)